HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

Vaccine

Volumn 26, Issue 52, 2008, Pages 6844-6851

  Joura, Elmar A ^a   Kjaer, Susanne K ^b   Wheeler, Cosette M ^c   Sigurdsson, Kristján ^d   Iversen, Ole Erik ^e   Hernandez Avila, Mauricio ^f   Perez, Gonzalo ^g   Brown, Darron R ^h   Koutsky, Laura A ⁱ   Tay, Eng Hseon ^j   García, Patricia ^k   Ault, Kevin A ^l   Garland, Suzanne M ^m   Leodolter, Sepp ^a   Olsson, Sven Eric ⁿ   Tang, Grace W K ^o   Ferris, Daron G ^p   Paavonen, Jorma ^q   Lehtinen, Matti ^r   Steben, Marc ^s   Bosch, Xavier ^t   Dillner, Joakim ^u   Kurman, Robert J ^v   Majewski, Slawomir ^w   Muñoz, Nubia ^x   Myers, Evan R ^y   Villa, Luisa L ^z   Taddeo, Frank J ^aa   Roberts, Christine ^aa   Tadesse, Amha ^aa   Bryan, Janine ^aa   Lupinacci, Lisa C ^aa   Giacoletti, Katherine E D ^aa   Lu, Shuang ^aa   Vuocolo, Scott ^aa   Hesley, Teresa M ^aa   Haupt, Richard M ^aa   Barr, Eliav ^aa   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d National Cancer Detection Clinic   (Iceland)

^e UNIVERSITY OF BERGEN   (Norway)

^f INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^g UNIVERSIDAD DEL ROSARIO   (Colombia)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^k UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^l EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m ROYAL WOMEN'S HOSPITAL   (Australia)

ⁿ DANDERYD HOSPITAL   (Sweden)

^o UNIVERSITY OF HONG KONG   (Hong Kong)

^p MEDICAL COLLEGE OF GEORGIA   (United States)

^q HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^r UNIVERSITY OF TAMPERE   (Finland)

^s INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^t BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^u LUND UNIVERSITY   (Sweden)

^v JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^w MEDICAL UNIVERSITY OF WARSAW   (Poland)

^x Instituto Nacional de Cancerología   (Colombia)

^y DUKE UNIVERSITY MEDICAL CENTER   (United States)

^z LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^aa MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Human Papillomavirus; Humoral immunity; Immune memory

Indexed keywords

PLACEBO; SILGARD; UNCLASSIFIED DRUG; VIRUS ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADOLESCENT; ANTIBODIES, VIRAL; CONDYLOMATA ACUMINATA; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VAGINA; VAGINAL SMEARS; VULVA; YOUNG ADULT;

EID: 56949087305     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.073     Document Type: Article

References (32)

1. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 102 May (5A) (1997) 3-8
2. Bosch F.X., and de Sanjose S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 31 June (2003) 3-13
3. Melbye M., and Frisch M. The role of human papillomaviruses in anogenital cancers. Semin Cancer Biol 8 (1998) 307-313
4. Goffin F., Mayrand M.H., Gauthier P., Alobaid A., Lussier C., Provencher D., et al. High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia. J Med Virol 78 June (6) (2006) 814-819
5. Gross G., and Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol 193 (2004) 35-44
6. Daling J.R., Madeleine M.M., Schwartz S.M., Shera K.A., Carter J.J., McKnight B., et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 84 February (2002) 263-270
7. Fakhry C., and Gillison M.L. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24 June (17) (2006) 2606-2611
8. Ferenczy A., Mitao M., Nagai N., Silverstein S.J., and Crum C.P. Latent papillomavirus and recurring genital warts. N Engl J Med 313 (1985) 784-788
9. Clifford G.M., Rana R.K., Franceschi S., Smith J.S., Gough G., and Pimenta J.M. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 1157-1164
10. Gissmann L., Wolnik L., Ikenberg H., Koldovsky U., Schnurch H.G., and zur H.H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci USA 80 January (2) (1983) 560-563
11. Kashima H.K., Mounts P., and Shah K. Recurrent respiratory papillomatosis. Obstet Gynecol Clin North Am 23 September (3) (1996) 699-706
12. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
13. Joura E.A., Leodolter S., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet 369 (2007) 1693-1702
14. The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 (2007) 1861-1868
15. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 19 (2007) 1928-1943
16. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 11 (2006) 1459-1466
17. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-dinh-Desmarquet C., Orth G., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69 6 (1995) 3959-3963
18. Kirnbauer R., Chandrachud L.M., O'neil B.W., Wagner E.R., Grindlay G.J., Armstrong A., et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219 (1996) 37-44
19. Suzich J.A., Ghim S., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92 (1995) 11553-11557
20. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 19 (2007) 1915-1927
21. Lowe R.S., Brown D.R., Bryan J.T., Cook J.C., George H.A., Hofmann K.J., et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 176 (1997) 1141-1145
22. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 21 (2002) 1645-1651
23. Ault K., Giuliano A.R., Edwards R., Tamms G., Kim L.-L., Smith J.F., et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 22 23/24 (2004) 3004-3007
24. Solomon D., Davey D., Kurman R., Moriarty A., O'Connor D., Prey M., et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 287 16 (2002) 2114-2119
25. Opalka D., Lachman C.E., MacMullen S.A., Jansen K.U., Smith J.F., Chirmule N., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 10 1 (2003) 108-115
26. World Heather Organization Expert Committe on Biological Standardization. Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. http://www.hoint/biologicals/publications/trs/areas/vaccines/human_papil lomavirus/HPVg%20Final%20BS%202050%20pdf. Accessed August 2, 2007; 2006.
27. Block S.L., Nolan T., Sattler C., Barr E., Giacoletti K.E., Marchant C.D., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118 November (5) (2006) 2135-2145
28. Dias D., Van Doren J., Schlottmann S., Kelly S., Puchalski D., Ruiz W., et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18. Clin Diagn Lab Immunol 12 8 (2005) 959-969
29. Yeager M.D., Aste-Amezaga M., Brown D.R., Martin M.M., Shah M.J., Cook J.C., et al. Neutralization of human papillomavirus (HPV) pseudovirions: a noval and efficient approach to detect and characterize HPV neutralizing antibodies. Virology 278 (2000) 570-577
30. Olsson S.-E., Villa L.L., Costa R., Petta C., Andrade R., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like-particle vaccine. Vaccine 25 (2007) 4931-4939
31. Giuliano A., Lazcano-Ponce E., Villa L., Nolan T., Marchant C.D., Radley D., et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16 and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 196 October (2007) 1153-1162 © 2007 by the Infectious Diseases Society of America
32. Christensen N.D., Cladel N.M., and Reed C.A. Postattachment neutralization of papillomaviruses by monoclonal and polyclonal antibodies. Virology 207 February (1) (1995) 136-142